NO20051966L - Nye pyrimidinamidderivater og anvendelse derav - Google Patents
Nye pyrimidinamidderivater og anvendelse deravInfo
- Publication number
- NO20051966L NO20051966L NO20051966A NO20051966A NO20051966L NO 20051966 L NO20051966 L NO 20051966L NO 20051966 A NO20051966 A NO 20051966A NO 20051966 A NO20051966 A NO 20051966A NO 20051966 L NO20051966 L NO 20051966L
- Authority
- NO
- Norway
- Prior art keywords
- derivatives
- pyrimidinamide
- disease
- new
- benzoylaminophenyl
- Prior art date
Links
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical class NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- NGNJTDQLHYCUGI-UHFFFAOYSA-N n-[3-[(4-pyridin-4-ylpyrimidin-2-yl)amino]phenyl]benzamide Chemical class C=1C=CC=CC=1C(=O)NC(C=1)=CC=CC=1NC(N=1)=NC=CC=1C1=CC=NC=C1 NGNJTDQLHYCUGI-UHFFFAOYSA-N 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0222514.2A GB0222514D0 (en) | 2002-09-27 | 2002-09-27 | Organic compounds |
| PCT/EP2003/010724 WO2004029038A1 (en) | 2002-09-27 | 2003-09-26 | Novel pyrimidineamide derivatives and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20051966L true NO20051966L (no) | 2005-04-22 |
Family
ID=9944917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051966A NO20051966L (no) | 2002-09-27 | 2005-04-22 | Nye pyrimidinamidderivater og anvendelse derav |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7655669B2 (de) |
| EP (1) | EP1546127B1 (de) |
| JP (2) | JP4463685B2 (de) |
| KR (2) | KR100876055B1 (de) |
| CN (1) | CN100404528C (de) |
| AT (1) | ATE369355T1 (de) |
| AU (1) | AU2003270277B2 (de) |
| BR (1) | BR0314797A (de) |
| CA (1) | CA2499822C (de) |
| DE (1) | DE60315479T2 (de) |
| DK (1) | DK1546127T3 (de) |
| EC (1) | ECSP055701A (de) |
| ES (1) | ES2288615T3 (de) |
| GB (1) | GB0222514D0 (de) |
| MX (1) | MXPA05003253A (de) |
| NO (1) | NO20051966L (de) |
| NZ (1) | NZ538930A (de) |
| PL (1) | PL374443A1 (de) |
| PT (1) | PT1546127E (de) |
| RU (1) | RU2378267C2 (de) |
| SI (1) | SI1546127T1 (de) |
| WO (1) | WO2004029038A1 (de) |
| ZA (1) | ZA200502304B (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0222514D0 (en) * | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| US7232825B2 (en) * | 2003-05-02 | 2007-06-19 | Guoqing P Chen | Phenylaminopyrimidine derivatives and methods of use |
| GB0325031D0 (en) * | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| DE10352979A1 (de) * | 2003-11-13 | 2005-06-09 | Merck Patent Gmbh | Pyridopyrimidinone |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| BRPI0514691A (pt) | 2004-08-31 | 2008-06-17 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo |
| US8735415B2 (en) | 2004-09-09 | 2014-05-27 | Natco Pharma Limited | Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
| US7939541B2 (en) | 2004-09-09 | 2011-05-10 | Natco Pharma Limited | Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
| BRPI0515081B8 (pt) * | 2004-09-09 | 2021-05-25 | Natco Pharma Ltd | composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida |
| CN1972917B (zh) * | 2004-12-31 | 2010-08-25 | 孙飘扬 | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 |
| CN1939910A (zh) | 2004-12-31 | 2007-04-04 | 孙飘扬 | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 |
| MX2007009135A (es) * | 2005-01-28 | 2007-09-06 | Novartis Ag | Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulacion de la actividad de la cinasa tie-2. |
| MY146795A (en) | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
| US20100216791A1 (en) * | 2006-08-17 | 2010-08-26 | Astrazeneca | Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors |
| EP2251042A3 (de) | 2006-09-22 | 2012-05-02 | Novartis AG | Optimierung der Behandlung von positiver Philadelphia Leukemia mit ABL Tyrosine Kinase Hemmern |
| CA2668190A1 (en) * | 2006-11-03 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US7550591B2 (en) * | 2007-05-02 | 2009-06-23 | Chemagis Ltd. | Imatinib production process |
| MX2009011950A (es) * | 2007-05-04 | 2009-12-11 | Irm Llc | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. |
| AU2008247442B2 (en) | 2007-05-04 | 2013-01-10 | Irm Llc | Compounds and compositions as c-kit and PDGFR kinase inhibitors |
| US8242271B2 (en) * | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| PL2190825T3 (pl) | 2007-08-22 | 2014-09-30 | Novartis Ag | Związki 5-(4-(chlorowcoalkoksy)-fenylo)-pirymidyno-2-aminowe i kompozycje jako inhibitory kinazy |
| CN101784539A (zh) | 2007-08-22 | 2010-07-21 | Irm责任有限公司 | 作为激酶抑制剂的2-杂芳基氨基嘧啶衍生物 |
| US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
| WO2011154846A2 (en) * | 2010-05-11 | 2011-12-15 | Mahesh Kandula | Compound, synthesis, composition and uses thereof |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| JP2022523562A (ja) * | 2019-03-05 | 2022-04-25 | ホンイー アンド アソシエイツ エルエルシー | 神経変性疾患および癌の治療のための化合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3751742T3 (de) | 1986-01-13 | 2002-11-21 | American Cyanamid Co., Wayne | 4,5,6-Substituierte 2-Pyrimidinamine |
| US5215989A (en) | 1989-12-08 | 1993-06-01 | Merck & Co., Inc. | Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| TW225528B (de) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
| JPH08503971A (ja) | 1993-10-01 | 1996-04-30 | チバ−ガイギー アクチェンゲゼルシャフト | ピリミジンアミン誘導体及びその調製のための方法 |
| ITMI992711A1 (it) | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
| US7087608B2 (en) | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
| GB0025820D0 (en) | 2000-10-20 | 2000-12-06 | Novartis Ag | Organic compounds |
| EP1721609A3 (de) * | 2001-05-16 | 2007-01-31 | GPC Biotech AG | Pyridylpyrimidinderivate als effektive Verbindungen gegen Prioninfektionen und prion Erkrankungen |
| GB0222514D0 (en) * | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| ATE476686T1 (de) | 2003-12-23 | 2010-08-15 | Koninkl Philips Electronics Nv | Bestrahlungsverfahren |
-
2002
- 2002-09-27 GB GBGB0222514.2A patent/GB0222514D0/en not_active Ceased
-
2003
- 2003-09-26 EP EP03750639A patent/EP1546127B1/de not_active Expired - Lifetime
- 2003-09-26 AT AT03750639T patent/ATE369355T1/de not_active IP Right Cessation
- 2003-09-26 AU AU2003270277A patent/AU2003270277B2/en not_active Ceased
- 2003-09-26 KR KR1020057005204A patent/KR100876055B1/ko not_active Expired - Fee Related
- 2003-09-26 DK DK03750639T patent/DK1546127T3/da active
- 2003-09-26 PL PL03374443A patent/PL374443A1/xx not_active Application Discontinuation
- 2003-09-26 BR BR0314797-5A patent/BR0314797A/pt not_active IP Right Cessation
- 2003-09-26 NZ NZ538930A patent/NZ538930A/en unknown
- 2003-09-26 CA CA2499822A patent/CA2499822C/en not_active Expired - Fee Related
- 2003-09-26 JP JP2004539039A patent/JP4463685B2/ja not_active Expired - Fee Related
- 2003-09-26 US US10/528,913 patent/US7655669B2/en not_active Expired - Fee Related
- 2003-09-26 DE DE60315479T patent/DE60315479T2/de not_active Expired - Lifetime
- 2003-09-26 WO PCT/EP2003/010724 patent/WO2004029038A1/en not_active Ceased
- 2003-09-26 RU RU2005113153/04A patent/RU2378267C2/ru not_active IP Right Cessation
- 2003-09-26 SI SI200331014T patent/SI1546127T1/sl unknown
- 2003-09-26 ES ES03750639T patent/ES2288615T3/es not_active Expired - Lifetime
- 2003-09-26 KR KR1020077019251A patent/KR20070098940A/ko not_active Ceased
- 2003-09-26 CN CNB038232138A patent/CN100404528C/zh not_active Expired - Fee Related
- 2003-09-26 PT PT03750639T patent/PT1546127E/pt unknown
- 2003-09-26 MX MXPA05003253A patent/MXPA05003253A/es active IP Right Grant
-
2005
- 2005-03-18 ZA ZA200502304A patent/ZA200502304B/en unknown
- 2005-03-23 EC EC2005005701A patent/ECSP055701A/es unknown
- 2005-04-22 NO NO20051966A patent/NO20051966L/no not_active Application Discontinuation
-
2009
- 2009-10-09 JP JP2009235252A patent/JP5178681B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1546127T3 (da) | Nye pyrimidinamidderivater og anvendelse deraf | |
| DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| DK1636236T3 (da) | Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer | |
| WO2004005281A8 (en) | Inhibitors of tyrosine kinases | |
| MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
| NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
| NO20040547L (no) | Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse. | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| BR0312722A (pt) | Derivados de pirazol heterobicìclico como inibidores de qinase | |
| BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| SE0002729D0 (sv) | Novel compound form | |
| DE50312224D1 (de) | Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel | |
| MXPA05014143A (es) | Derivados de cumarina para el tratamiento de trastornos oftalmicos. | |
| NO20030021L (no) | Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV | |
| TW200700075A (en) | Roflumilast and integrin inhibitor combination and method of treatment | |
| DE60327249D1 (de) | Anthranilsäureamide und ihre pharmazeutische verwendung | |
| DE50304524D1 (de) | Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole | |
| ECSP12005525A (es) | Inhibidores de cinasas de tirosina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |